Fusion nano vesicle as well as preparation method and application thereof
Through physical extrusion, aloe vera and human mesenchymal cell vesicles were fused to prepare fusion nanovesicles with both functional characteristics, solving the problems of low fusion efficiency and instability in the existing technology, achieving efficient biological synergy, and suitable for skin repair and tumor immunotherapy.
Patent Information
- Application Number
- CN202510814999.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-06-18
- Publication Date
- 2025-09-02
AI Technical Summary
The fusion process of existing fusion vesicles is complex, the fusion efficiency is low, and the biological functions of fusion vesicles are unstable, making it difficult to meet the treatment needs of complex diseases.
Through physical extrusion, extracellular vesicles from aloe vera and extracellular vesicles from human mesenchymal stem cells are fused to prepare fusion nanovesicles with both functional characteristics. The specific steps include centrifugation, filtration, purification and mixing at a protein content ratio of 1-20:1-10 and extruding through a 0.22 μm needle filter.
It has achieved efficient fusion, and the fusion vesicles have shown significant synergistic effects in antioxidant and wound healing, with stable structure, controllable cost, flexible application, and are suitable for skin repair, inflammatory diseases and tumor immunotherapy.
Smart Images

Figure CN120570858A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of nano preparations, and in particular relates to a fusion nano vesicle and a preparation method and application thereof. Background Art
[0002] Nanovesicles are small vesicles released by cells that carry substances and information between cells and can be used for drug delivery. In existing research, nanovesicles derived from various cell sources have shown great potential in the field of tumor treatment. Mesenchymal stem cells have the ability to differentiate in multiple directions. They are a type of adult stem cell derived from tissues such as bone marrow, umbilical cord, fat, and gums that have high self-renewal and multidirectional differentiation potentials. They can also secrete a variety of cytokines and growth factors, and have immune regulation, tissue repair, and anti-inflammatory effects. Plant-derived vesicles can not only be used as drug delivery systems, but also have the advantages of being naturally non-toxic, easy to extract, and having low immunogenicity, making them an environmentally friendly biomaterial.
[0003] However, single-source nanovesicles still have functional limitations, making them difficult to meet the needs of treating complex diseases. Existing research has successfully demonstrated the feasibility of fusogenic nanovesicles and their enhanced therapeutic efficacy. Patent CN113769106A discloses fusogenic cell membrane nanovesicles for tumor immunotherapy, their preparation methods, and applications. This patent involves mixing two or more single cell membrane vesicle components, ultrasonically treating them, and then extruding them through a micro-pusher to form the fusogenic cell membrane nanovesicles. However, this invention struggles to achieve spontaneous fusion, typically requiring external intervention (such as ultrasonication) to promote membrane fusion. In the study "Plant exosomes fused with engineered mesenchymal stem cell-derived nanovesicles for synergistic therapy of autoimmune skin disorders", Chen Hongbo et al. (2023) designed fused nanovesicles derived from grapefruit exosome-like nanovesicles and gingival mesenchymal stem cell membrane vesicles. Ensuring that the fused vesicles retain the key biological functions of vesicles from both sources and achieve synergistic enhancement rather than mutual antagonism is the core challenge facing current technology. Summary of the Invention
[0004] To address the problems of complex fusion processes, low fusion efficiency, and unstable biological functions of existing fusogenic vesicles, there is an urgent need to develop fusogenic vesicles with simple preparation methods, diverse biological functions, and a wide range of applications. The present invention aims to provide fusogenic nanovesicles, their preparation methods, and applications. By physically extruding extracellular vesicles derived from aloe vera and human mesenchymal stem cells to achieve membrane fusion, a fusogenic vesicle with the functional properties of both is prepared.
[0005] In order to achieve the above object, the technical solution of the present invention is as follows: In a first aspect, the present invention discloses a fusion nanovesicle (Hybrid-EVs), which includes a membrane structure formed by the fusion of human mesenchymal cell vesicles (MSC-EVs) and plant exosomes; the human mesenchymal cell vesicles are human umbilical cord mesenchymal cell vesicles; and the plant exosomes are aloe exosomes (Aloe-EVs).
[0006] Specifically, the protein content ratio of the plant exosomes to the mesenchymal cell vesicles in the nanovesicles is 1-20:1-10.
[0007] In a second aspect, the present invention provides a method for preparing the aforementioned fusion nanovesicles, comprising the following steps: (1) Aloe vera and human umbilical cord mesenchymal cells were centrifuged, filtered, and purified to obtain aloe vera exosomes and human umbilical cord mesenchymal cell vesicles; (2) The human umbilical cord mesenchymal cell vesicles obtained in step (1) and aloe exosomes were mixed at a protein content ratio of 1-20:1-10, and squeezed through a needle filter to obtain an extrudate; after the extrudate was centrifuged, the precipitate was resuspended in PBS to obtain fusion nanovesicles.
[0008] Specifically, the pore size of the needle filter in step (2) is 0.2-0.4 μm, preferably 0.22 μm.
[0009] Specifically, the number of extrusions in step (2) is 1-10 times.
[0010] Specifically, the purification method in step (1) is selected from any one of the following: sucrose gradient centrifugation, PEG precipitation, ultracentrifugation, ultrafiltration, or size exclusion chromatography.
[0011] In some embodiments, the method of purification is selected from ultracentrifugation.
[0012] Specifically, the filtration in step (1) is performed by membrane filtration, and specifically, the pore size of the membrane is 0.22 μm.
[0013] Specifically, the centrifugal speed in step (1) is 300-10000 g, and the centrifugal time is 10-70 min.
[0014] In a third aspect, the present invention provides use of the aforementioned fusion nanovesicles or the fusion nanovesicles prepared by the aforementioned preparation method in the preparation of drugs for skin repair or inflammatory diseases.
[0015] Specifically, the inflammatory disease is selected from rheumatoid arthritis, psoriasis or autoimmune diseases.
[0016] In a fourth aspect, the present invention provides use of the aforementioned fusion nanovesicles or the fusion nanovesicles prepared by the aforementioned preparation method in the preparation of drugs for tumor immunotherapy.
[0017] In a fifth aspect, the present invention provides the use of the aforementioned fusion nanovesicles or the fusion nanovesicles prepared by the aforementioned preparation method in a drug delivery platform.
[0018] Compared with the prior art, the present invention has the following beneficial effects: (1) High fusion efficiency: The membranes of the two vesicles were fully fused by squeezing through a needle filter with a pore size of 0.22 μm. Flow cytometry double-labeling analysis showed that more than 60% of the fused vesicles contained the characteristics of the two components (double fluorescence positive).
[0019] (2) Significant functional synergy, far superior to single vesicles: Fusion vesicles carry the active ingredients of both aloe vera EVs and MSC-EVs, possessing "dual efficacy." In terms of antioxidant activity, the total antioxidant function of fusion vesicles is stronger than that of any single EV; in terms of promoting wound healing, the promotion of fibroblast proliferation and migration is also more significant. Fusion vesicles can simultaneously play multiple roles in complex physiological environments, such as scavenging oxygen free radicals, inhibiting inflammatory responses, and promoting cell proliferation and migration.
[0020] (3) Stable structure, complete retention of key active substances: The fused nanovesicles exhibit similar morphology and stability to the original vesicles. Nanoparticle size tracking analysis shows that the fusion process does not destroy the key protein markers on the vesicle membrane and the internal functional molecules.
[0021] (4) Controllable costs and increased production capacity: Aloe vera plants are easy to cultivate on a large scale and their exosome extraction rate is relatively high. For every MSC-EVs fused, multiple aloe vera EVs can be added, thereby amplifying the total amount of the product.
[0022] (5) Strong application flexibility: By selecting plant EVs from different sources or changing the type of stem cells, fusion vesicles with specific functional combinations can be customized. At the same time, fusion vesicles can also be further functionalized as drug carriers, such as loading small molecule drugs, siRNA, etc., to improve their delivery efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 The results of the antioxidant capacity (T-AOC) test of the fusion nanovesicles prepared in Example 1 and Example 2 are shown; Figure 2 The effect of different extrusion times on fusion nanovesicles; Figure 3 Characterization analysis of MSC-EVs, Aloe-EVs, and Hybrid-EVs; the left column shows the particle size distribution as shown by NTA; the middle column shows the morphological characteristics of the transluminal TEM images; the right column shows the immunofluorescence staining images, showing the expression of surface markers (red / green fluorescence) and nuclear staining (blue); Figure 4 Coomassie Brilliant Blue staining results of MSC-EVs, Aloe-EVs, and Hybrid-EVs; Figure 5 The results of qPCR detection of mRNA expression levels of inflammatory factors IL-6 and TNF-α; Figure 6 A shows the migration ability changes of different groups, B shows the migration rate statistics of different groups, and C shows the cell viability results of different groups detected by CCK-8. Figure 7 The results of DCFH-DA flow cytometry detection of ROS levels in different groups; In the accompanying drawings, “*” indicates P<0.05, i.e., the result is statistically significant; “**” indicates P<0.01, i.e., the result is highly statistically significant. DETAILED DESCRIPTION
[0024] Unless otherwise defined, the technical terms used in the following examples have the same meanings as commonly understood by those skilled in the art to which this invention belongs. The experimental reagents used in the following examples, unless otherwise specified, are conventional biochemical reagents; the experimental methods described, unless otherwise specified, are conventional methods.
[0025] Experimental Materials: (1) Aloe vera material: Select mature Aloe vera plants that are more than two years old, and use their thick leaves as the raw material for exosome (EVs) extraction. Collect several fresh Aloe vera leaves on the same day, remove the epidermal hairs, rinse and set aside.
[0026] (2) MSC cells: Human umbilical cord mesenchymal stem cells (hUC-MSC) derived from healthy donors. The cell donor was ethically approved. The cells were cultured in low-glucose DMEM medium (containing 10% fetal bovine serum and Pen / Strep double-antibody) and expanded at 37°C and 5% CO2. At the fourth passage, the cells were replaced with exosome-free serum medium and cultured for another 48 hours to collect exosomes.
[0027] Experimental consumables and instruments: (1) Ultracentrifuge (Ti70), ultrafiltration centrifuge tubes (molecular weight cutoff 100 kDa), PBS buffer, and 0.22 μm syringe filter; (2) Analytical characterization instruments: transmission electron microscope (TEM, JEOL JEM-2100), nanoparticle tracking analyzer (NTA, Malvern NanoSight NS300), dynamic light scattering (DLS, Malvern Zetasizer), fluorescence microscope (with red / green fluorescence channels), and Coomassie brilliant blue staining solution.
[0028] (3) Functional experiment reagents: LPS, mouse macrophage RAW264.7, CCK-8 cell proliferation detection kit, mouse fibroblast L929, cell scratch experiment equipment, etc.
[0029] Example 1 A method for preparing fusion nanovesicles 1.1 Extraction of Aloe-EVs (1) Peel the fresh aloe vera leaves and extract the gel. Add an equal volume of sterile PBS and homogenize in a blender (keep at low temperature to prevent degradation of the active substance). (2) The homogenate was centrifuged at 300 × g for 10 min at 4°C to remove crude fibers and cells, at 2000 × g for 20 min to remove large debris, and at 10,000 × g for 30 min to remove large vesicles and organelles. (3) Collect the supernatant and filter it through a 0.22 μm filter membrane. Transfer the filtrate to an ultracentrifuge tube and centrifuge at 100,000 × g for 70 min. Discard the supernatant. Add PBS to the tube to resuspend the pellet and centrifuge again at 100,000 × g for 70 min. The final pellet is the crude Aloe EVs (Aloe-EVs).
[0030] 1.2 Extraction of human umbilical cord mesenchymal cell vesicles (MSC-EVs) (1) Collect the culture supernatant of human umbilical cord mesenchymal stem cells (hUC-MSCs), centrifuge at 300 × g for 10 min at 4°C to remove cells, centrifuge at 2000 × g for 20 min to remove cell debris, and centrifuge at 10000 × g for 30 min to remove large vesicles; (2) The supernatant was filtered through a 0.22 μm filter membrane and placed in an ultracentrifuge tube to precipitate EVs at 100,000 × g for 70 min. The MSC-EV pellet was resuspended in PBS and centrifuged again.
[0031] 1.3 Determination of protein content in Aloe-EVs and MSC-EVs 1.4 Formation of fusogenic vesicles (1) The Aloe-EVs and MSC-EVs suspensions obtained in the previous step were mixed at protein ratios of 20:1, 10:1, 5:1, 1:1, 1:10, and 1:5; (2) Take a total volume of 1 mL of the mixture and add it to a 0.22 μm pore size needle filter. At room temperature, use a syringe to push the sample through the filter membrane, squeezing it through the membrane once in total; (3) The extrudate was collected and centrifuged at 1500 × g for 30 min at 4°C to remove any large vesicle aggregates that may exist. The fused vesicles were then precipitated by ultracentrifugation at 100,000 × g for 1 h. (4) Discard the supernatant and gently resuspend the precipitate in 200 μL PBS to obtain a high-concentration fusion aloe vera-MSC vesicle sample (Hybrid-EVs).
[0032] Example 2 A method for preparing fusion nanovesicles The Aloe-EV and MSC-EV suspensions from Examples 1.1 and 1.2 were directly mixed at protein ratios of 20:1, 10:1, 5:1, 1:1, 1:10, and 1:5. Fusogenic vesicles were then pelleted by ultracentrifugation at 100,000 × g for 1 h. The supernatant was discarded, and the pellet was gently resuspended in 200 μL of PBS to obtain fusogenic nanovesicles.
[0033] Effect Example 1 In order to preliminarily detect the antioxidant effect of the fusion nanovesicles prepared in Examples 1 and 2, the antioxidant effect was determined by a total antioxidant capacity (T-AOC) detection kit.
[0034] The experimental results are as follows Figure 1As shown, “Sample 1” represents “the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 20:1 in Example 1”; “Sample 2” represents “the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 10:1 in Example 1”; “Sample 3” represents “the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 5:1 in Example 1”; “Sample 4” represents “the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 1:1 in Example 1”; “Sample 5” represents “the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 1:10 in Example 1”; “Sample 6” represents “the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 1:5 in Example 1”; “Control Sample "Control sample 1" represents "the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 20:1 in Example 2"; "Control sample 2" represents "the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 10:1 in Example 2"; "Control sample 3" represents "the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 5:1 in Example 2"; "Control sample 4" represents "the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 1:1 in Example 2"; "Control sample 5" represents "the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 1:10 in Example 2"; "Control sample 6" represents "the fusion nanovesicles prepared by the protein content of Aloe-EVs and MSC-EVs suspension at 1:5 in Example 2"; The results showed that the total antioxidant capacity of "Sample 2" was significantly superior to that of the other samples, indicating that the fused nanovesicles prepared from a 10:1 protein ratio of Aloe-EVs to MSC-EVs suspension possessed superior total antioxidant capacity. The total antioxidant capacity of "Sample 2" was superior to that of "Control Sample 2," demonstrating that the technical solution of the present invention, achieved through a 0.22 μm pore size needle filter, is superior to the conventional method of directly mixing vesicles from different sources.
[0035] In order to detect the effect of the number of times the fusion nanovesicles were squeezed through a 0.22 μm pore size needle filter on their properties, "Sample 2" was used as a control. The preparation method of "Sample 2" was used to perform the extrusion experiments for 3, 5, and 10 times, respectively. The BCA content of the fusion nanovesicles was detected. The results are shown in Figure 2. Figure 2 As shown, the technical solution of the present invention has better effects.
[0036] Effect Example 2 In this effect example, “Hybrid-Evs” represents “Sample 2”, “Aloe-EVs” represents “Aloe exosomes in Example 1”, and “MSC-EVs” represents “Human umbilical cord mesenchymal cell vesicles MSC-EVs in Example 1”.
[0037] (1) Nanoparticle Tracking Analyzer (NTA) assay: The NTA of Aloe-EVs, MSC-EVs, and Hybrid-EVs was measured. The results were as follows: Figure 3 As shown in the middle left column, the particle size distribution of Aloe-EVs is around 50-200 nm, the particle size distribution of MSC-EVs is around 100-150 nm, and the particle size distribution of Hybrid-EVs is around 150 nm, and the size distribution is unimodal and uniform.
[0038] (2) Transmission electron microscopy (TEM) detection: 5 μL of Aloe-EVs, MSC-EVs, and Hybrid-EVs samples were dropped onto a copper mesh carbon film. After standing for 1 min, the excess liquid was removed and negatively stained with 2% sodium phosphotungstate for 5 min. The results are shown in Figure 2. Figure 3 As shown in the middle column, hybrid EVs exhibit a typical round vesicle structure with clear edges, ranging in size from 100–200 nm, and exhibit no signs of breakage or abnormal aggregation. This is indistinguishable from the morphology of isolated Aloe-EVs and MSC-EVs, indicating that the fusion vesicle structure is intact and stable.
[0039] (3) Fluorescence co-localization detection: Aloe-EVs and MSC-EVs were labeled with lipid dyes PKH67 (green) and DiI (red). After incubation and staining, free dyes were removed by ultracentrifugation. The two pre-stained EVs were fused and extruded according to the above steps. The resulting hybrid-EVs were dropped onto a glass slide and observed under a fluorescence microscope. The results are shown in Figure 2. Figure 3 The middle right column shows that a single vesicle contains both green and red fluorescent dyes, and obvious yellow overlapping fluorescent signals appear in Hybrid-EVs, which proves that Aloe-EVs and MSC-EVs have successfully fused into the same vesicle. Calculations show that the proportion of fused nanovesicles in the total particles is close to 60%.
[0040] (4) Coomassie Brilliant Blue staining test: Western Blot results of Aloe-EVs, MSC-EVs, and Hybrid-EVs samples are as follows Figure 4As shown, Aloe-EVs have relatively low protein content, weaker band intensity, and a limited variety of proteins. MSC-EVs exhibit the richest protein content, showing a broad distribution of protein bands in the 25-180 kDa range, with a particularly prominent band in the 70-100 kDa region. Hybrid-EVs display an intermediate protein profile, retaining the rich protein profile of MSC-EVs while integrating the protein components of Aloe-EVs. This difference in protein composition is highly consistent with the results of functional experiments. The rich protein content of MSC-EVs corresponds to their optimal anti-inflammatory effect, while Hybrid-EVs achieve a synergistic anti-inflammatory effect through protein combination, indicating that the protein composition of different vesicles is an important molecular basis for their functional differences.
[0041] Effect Example 3 In this example, "Hybrid-EVs" represents "Sample 2", "Aloe-EVs" represents "Aloe exosomes in Example 1", "MSC-EVs" represents "Human umbilical cord mesenchymal cell vesicles MSC-EVs in Example 1", and "Control" represents "PBS solution".
[0042] 3.1 Anti-inflammatory effect test Mouse macrophage RAW264.7 cells were used to establish an LPS-induced inflammation model (100 ng / mL stimulation for 6 h), and then equal amounts of Aloe-EVs, MSC-EVs, or Hybrid-EVs were added and cultured for another 24 h. The mRNA expression levels of inflammatory factors IL-6 and TNF-α were detected by qPCR. Figure 5 As shown in the results, the Aloe-EVs and MSC-EVs groups decreased the expression levels of IL-6 and TNF-α by approximately 40%, respectively, while the Hybrid-EVs group downregulated by approximately 70%, which was significantly better than any single group, indicating that the fusion vesicles have a synergistic enhancing effect in inhibiting inflammation.
[0043] 3.2 Proliferation and migration ability After establishing a scratch injury model with mouse fibroblasts L929, equal amounts of Aloe-EVs, MSC-EVs, or Hybrid-EVs were treated, and the scratch healing was observed at 24 h and 48 h.
[0044] Migration rate = (initial scratch width - scratch width after 24 hours) / initial scratch width × 100%.
[0045] The results are as follows Figure 6As shown in A and B, at 24 h, the scratches in the control group showed almost no healing, the migration rates of the Aloe-EVs and MSC-EVs groups were 1.5 times and 1.6 times that of the control, respectively, and that of the Hybrid-EVs group was 2.2 times; at 48 h, the migration rates of the Aloe-EVs and MSC-EVs groups were 45%, respectively, and the Hybrid-EVs group further increased to 55%, showing the strongest ability to promote migration.
[0046] In addition, the cell viability was detected by CCK-8. Figure 6 As shown in Figure C, although Hybrid-EVs only used 10 µL of Aloe-EVs and 1 µL of MSC-EVs stock solution during the preparation process, the total dosage was lower than that of the Aloe-EVs or MSC-EVs groups alone (both were 20 µL of stock solution), its proliferation-promoting effect was still slightly higher than that of the single vesicle group, suggesting that it has higher functional efficiency per unit EV dosage.
[0047] 3.3 Antioxidant effect The L929 oxidative stress model was induced by H2O2, and Aloe-EVs, MSC-EVs or Hybrid-EVs were added. After 24 hours of treatment, the intracellular ROS level was detected using DCFH-DA fluorescent probe combined with flow cytometry. Figure 7 As shown in the data, the ROS positivity rate in the injury model group was 68.6%, which was reduced to 55.7% and 62.1% in the Aloe-EVs and MSC-EVs treatment groups, respectively, and further reduced to 52.8% in the Hybrid-EVs group, the lowest among the three groups, indicating that its antioxidant capacity is stronger.
[0048] In summary, Hybrid-EVs show comprehensive advantages that are significantly superior to single-source EVs in anti-inflammation, proliferation / migration promotion, and anti-oxidation, and achieve stronger biological effects while using relatively less EVs stock solution, verifying its synergistic enhancement potential at the structural and functional levels, and has important biomedical application value.
Claims
1. A fusion nanovesicle, characterized in that: The fusion nanovesicles include a membrane structure formed by the fusion of mesenchymal cell vesicles and plant exosomes; the mesenchymal cell vesicles are human umbilical cord mesenchymal cell vesicles; and the plant exosomes are aloe exosomes.
2. The fusion nanovesicle according to claim 1, characterized in that The protein content ratio of the plant exosomes to the mesenchymal cell vesicles in the nanovesicles is 1-20:1-10.
3. The method for preparing the fusion nanovesicles according to claim 1 or 2, characterized in that: The following steps are involved: (1) Aloe vera and human umbilical cord mesenchymal cells were centrifuged, filtered, and purified to obtain aloe vera exosomes and human umbilical cord mesenchymal cell vesicles; (2) The human umbilical cord mesenchymal cell vesicles obtained in step (1) and aloe exosomes were mixed at a protein content ratio of 1-20:1-10, and squeezed through a needle filter to obtain an extrudate; after the extrudate was centrifuged, the precipitate was resuspended in PBS to obtain fusion nanovesicles.
4. The fusion nanovesicle according to claim 3, characterized in that The pore size of the needle filter in step (2) is 0.2-0.4 μm.
5. The fusion nanovesicle according to claim 3, characterized in that The number of extrusions in step (2) is 1-10 times.
6. The fusion nanovesicle according to claim 3, characterized in that The purification method in step (1) is selected from any one of the following: sucrose gradient centrifugation, PEG precipitation, ultracentrifugation, ultrafiltration, or size exclusion chromatography.
7. The fusion nanovesicle according to claim 3, characterized in that The centrifugal speed in step (1) is 300-10000 g, and the centrifugal time is 10-70 min.
8. Use of the fusogenic nanovesicle according to claim 1 or 2 or the fusogenic nanovesicle prepared by the preparation method according to any one of claims 3 to 7 in the preparation of drugs for skin repair or inflammatory diseases.
9. Use of the fusogenic nanovesicle according to claim 1 or 2 or the fusogenic nanovesicle prepared by the preparation method according to any one of claims 3 to 7 in the preparation of a drug for tumor immunotherapy.
10. Use of the fusogenic nanovesicle according to claim 1 or 2 or the fusogenic nanovesicle prepared by the preparation method according to any one of claims 3 to 7 in a drug delivery platform.
Citation Information
Cited By
Fusion vesicle, retinol loaded on fusion vesicle and preparation method and application of retinol loaded on fusion vesicle
CN120827506A
